<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am</td>
<td>Registration • 6:30 am - 12:30 pm</td>
</tr>
<tr>
<td>7:30 am</td>
<td>Welcome</td>
</tr>
<tr>
<td>8:00 am</td>
<td>Roundtables</td>
</tr>
<tr>
<td>8:30–10:00 am</td>
<td>International Perspectives</td>
</tr>
<tr>
<td>8:30–10:00 am</td>
<td>FLEPSI</td>
</tr>
<tr>
<td>9:00 am</td>
<td>Exhibits and Posters • 10:00 am - 4:00 pm</td>
</tr>
<tr>
<td>9:30 am</td>
<td>Short-term and Long-term Follow-up</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Exhibits and Posters • 10:00 am - 4:00 pm</td>
</tr>
<tr>
<td>10:30 am</td>
<td>Exhibits and Posters • 10:00 am - 4:00 pm</td>
</tr>
<tr>
<td>11:00 am</td>
<td>Exhibits and Posters • 10:00 am - 4:00 pm</td>
</tr>
<tr>
<td>12:00–1:30 pm</td>
<td>Exhibits and Posters • 10:00 am - 4:00 pm</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>Exhibits and Posters • 10:00 am - 4:00 pm</td>
</tr>
<tr>
<td>1:30 pm</td>
<td>Exhibits and Posters • 10:00 am - 4:00 pm</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>Exhibits and Posters • 10:00 am - 4:00 pm</td>
</tr>
<tr>
<td>2:30 pm</td>
<td>Exhibits and Posters • 10:00 am - 4:00 pm</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Exhibits and Posters • 10:00 am - 4:00 pm</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Exhibits and Posters • 10:00 am - 4:00 pm</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>Exhibits and Posters • 10:00 am - 4:00 pm</td>
</tr>
<tr>
<td>4:30 pm</td>
<td>Exhibits and Posters • 10:00 am - 4:00 pm</td>
</tr>
<tr>
<td>5:00 pm</td>
<td>Exhibits and Posters • 10:00 am - 4:00 pm</td>
</tr>
<tr>
<td>5:30 pm</td>
<td>Exhibits and Posters • 10:00 am - 4:00 pm</td>
</tr>
<tr>
<td>6:00 pm</td>
<td>Meet the Manufacturers</td>
</tr>
<tr>
<td>6:30 pm</td>
<td>Exhibits and Posters • 10:00 am - 4:00 pm</td>
</tr>
<tr>
<td>7:00 pm</td>
<td>Exhibits and Posters • 10:00 am - 4:00 pm</td>
</tr>
<tr>
<td>7:30 pm</td>
<td>Exhibits and Posters • 10:00 am - 4:00 pm</td>
</tr>
</tbody>
</table>

All listed times are Pacific Standard Time (PST).
Floorplan
Greater Tacoma Convention Center

Level 5
Exhibits
Posters
Receptions
Awards Ceremony

Level 3
Registration
Plenary Sessions
Innovate! Sessions
Roundtables
Association of Public Health Laboratories

**Vision:** A healthier world through quality laboratory systems

**Mission:** Shape national and global health outcomes by promoting the value and contributions of public health laboratories and continuously improving the public health laboratory system and practice.

The Association of Public Health Laboratories (APHL) is a non-profit 501(c)(3) organization representing governmental laboratories that monitor and detect public health threats, including emerging infectious disease surveillance, detection of metabolic and genetic conditions in newborns, water contamination identification and foodborne outbreak detection. APHL's members are state, local, county and city public health laboratories, state and local environmental health laboratories, state agricultural laboratories, corporations, individual and student members with an interest in public health laboratory issues, and organizations that share common goals with APHL.

**APHL is a National leader in:**
- Scientific Expertise
- Education and Training
- Health Policy
- Informatics
- Quality Assurance
- Workforce Development
- Laboratory Systems
- Global Laboratory Capacity

**APHL Board of Directors**

Daphne Ware, PhD, Mississippi, President  
Tim Southern, PhD, South Dakota, President-Elect  
Denise Toney, PhD, HCLD(ABB), Virginia, Past President  
Godfred Masinde, PhD, MBA, HCLD(ABB), San Francisco City/County, Secretary-Treasurer  
Sharon Massingale, PhD, HCLD/CC(ABB), Alabama, Member-at-Large  
Michael Pentella, PhD, D(ABMM), Iowa, Member-at-Large  
Scott Shone, PhD, HCLD(ABB), North Carolina, Member-at-Large  
Sally Flowers, PhD, Kansas, Public Health Associate Institutional Member  
Sanjib Bhattacharyya, PhD, Milwaukee, WI, Local Institutional Member  
Megan Crumpler, PhD, Orange County, CA, Local Institutional Member  
Scott Becker, MS, Chief Executive Officer (Ex-officio)
Welcome to the APHL 2022 Newborn Screening Symposium!

On behalf of the Planning Committee, we warmly welcome you to the APHL 2022 Newborn Screening (NBS) Symposium! The program is an exciting compilation of the efforts, enthusiasm and expertise of the NBS community.

You might want to hang on to your hat! Our plenary sessions will kick off on Sunday afternoon with a session highlighting patient and parent perspectives, with a chance to meet several families impacted by NBS. The keynote speakers for Monday have prepared provocative messages on where the NBS system is challenged and a look into advances in treatment that may help level the playing field for patients of NBS conditions. There will be 13 additional sessions during our time together.

Early mornings you will have the opportunity to attend roundtables, Innovate! sessions and the International Society of Neonatal Screening (ISNS) meeting. In the evenings there are opportunities to gather for some relaxation, including the meet the manufacturers and the off-site social. This makes for longs days full of excellent content!

We give a special invitation to stop by the Exhibit and Poster Hall, which will be open Sunday through Wednesday. Please meet the sponsors and corporate partners and see what they have on the horizon. Posters often are great sources of ideas for ways to make program improvement. We hope you will join us on Wednesday for the Awards Ceremony Lunch and recognize the wonderful contributions of the awardees. This year we feature two new APHL NBS Symposium Awards: the Achievements in Public Health Informatics in Newborn Screening and the Clinical Champion in Newborn Screening awards.

For those virtual attendees, we are excited to provide livestreaming of most of the sessions and poster viewing options through the online portal. We are sad you couldn’t join us in person and glad there is an opportunity for you to participate virtually!

Newborn screening is simple in its mission to save babies from death and disability. Moreover, it is a complex network of service and care providers that families, newborn screeners and clinical partners must navigate. That is why we are so glad you are joining us! You have experiences, skills and talents that we need. We look forward to spending these days learning with you and inspiring one another.

John Thompson, PhD, MPH, MPA
Director, Washington State Newborn Screening Program
Chair, APHL 2022 Newborn Screening Symposium Planning Committee
General Information

Location
The APHL 2022 NBS Symposium is being held at the Greater Tacoma Convention Center, 1500 Commerce, Tacoma, WA 98402, 253.830.6611. It is located in downtown Tacoma, walking distance to Puget Sound, numerous restaurants, shops and entertainment. The Marriott Tacoma Downtown Hotel is attached to the convention center and Hotel Murano is just across the street.

Registration
The in-person registration fee is $675; the virtual registration fee is $550. Online registration is still available.

APHL’s Federal ID number is 52-1800436. Cancellation policy: Registration cancelled 30 days prior to the symposium will be refunded less a $100 administrative fee. Registrations cancelled less than 30 days prior to the symposium will not be refunded.

Optional Tour of the Washington State Newborn Screening Laboratory
An optional tour of the Washington State Newborn Screening Laboratory has been arranged for Thursday afternoon, October 20. Pre-registration for this tour is required. Please meet near the symposium registration desk by 12:15 pm. The bus will leave promptly at 12:30 pm and will return no later than 4:00 pm.

Consent to Use Photographic Images
Registration and attendance at or participation in APHL conferences and other activities constitutes an agreement by the registrant to APHL’s use and distribution (both now and in the future) of the registrant’s or attendee’s image or voice, without compensation, in photographs, video and audio recordings of such events and activities.

Complimentary Wireless Internet
There is complimentary wireless internet in the public areas of the convention center. To access, follow the directions provided onsite.

Enhance Your Experience with the Mobile App
Search for “APHL Conferences” in your app store to download.

Access details on sessions, posters, exhibitors and sessions before the symposium and onsite; navigate the convention center; personalize your experience by tagging sessions, exhibitors and creating exportable notes. Receive alerts, reminders and changes in real time.
Thanks to Our Sponsors

Tote Bags
Hotel Key Cards
Morning Coffee Breaks
(Monday & Tuesday)

Padfolios
General Conference Support
Off-site Social

Short-term Follow-up Lunch

Connection Contest

Visit with the exhibitors and win prizes! Follow the instructions on the Exhibit Hall raffle card in your tote bag, recording each booth visit. When ALL of the boxes are filled, turn the card in at the registration desk no later than 3:00 pm on Wednesday, October 19. Be sure to include your name on the card.

Winners of the prizes will be announced starting at 3:30 pm on Wednesday in the Exhibit Hall. You must be present to win. Prizes include:

- Two coach tickets on Delta Airlines to anywhere within the continental United States
- Complimentary registration to the 2023 Newborn Screening Symposium
- One coach ticket on United Airlines to anywhere within the continental United States
- Apple Watch 7 compliments of EBF, Inc.
- “Welcome to the Northwest” gift package compliments of Astoria-Pacific
- Apple AirPod Pro compliments of Baebies
- NBS01—Dried Blood Spot Specimen Collection for Newborn Screening, 7th Edition and $50 Amazon gift card compliments of CLSI
- Beats Studio Buds (noise cancelling earbuds) compliments of OpenELIS Foundation
Continuing Education Credits

P.A.C.E.® Continuing Education Credits
APHL is an approved provider of continuing education programs in the clinical laboratory sciences through the American Society of Clinical Laboratory Science (ASCLS) P.A.C.E. program. Attendees may earn up to 21 P.A.C.E. credits by attending the entire symposium.

Certified Public Health Recertification Credits
APHL is an approved provider of Certified in Public Health (CPH) recertification credits through the National Board of Public Health Examiners (NBPHE). Attendees have the opportunity to earn up to 14 hours of credit by attending the entire symposium. APHL will not issue certificates of CPH credits earned. The attendee is responsible for keeping track of the hours earned.

Continuing Medical Education/Continuing Nursing Education/Certified Health Education Specialist/Genetic Counselor Credits
CME, CNE, CHES and Genetic Counseling CEUs (up to 21 credit hours) will be provided. Please refer to the tote bag insert for more information.

Safety Protocols
All in-person attendees, vendors, staff and support personnel at the APHL 2022 Newborn Screening Symposium must be fully vaccinated against COVID (1 round of J&J or 2 rounds of Pfizer or Moderna). APHL will require all in-person Newborn Screening Symposium attendees to upload their proof of vaccination card or waiver to CrowdPass (more details to follow).
Pre-departure testing and COVID boosters are optional, but highly recommend. If you test COVID positive prior to departure, please stay home. Well-fitting, high-quality masks (e.g., KF94, KN95 or better) are strongly encouraged, but not required.

If at any time you feel unwell, we ask that you alert a APHL 2022 Newborn Screening Symposium staff member and wear a mask. COVID-19 tests will be readily available for the duration of the symposium at the registration desk.
Please take these health protocols into consideration before registering for this meeting and include your emergency contact information in the registration form.
Not-to-Miss Events
All listed times are Pacific Standard Time (PST).

**Parent/Patient Panel**
Sunday, October 16 | 4:30–6:00 pm
Hear compelling personal accounts of how newborn screening impacts the lives of families. Follow their journeys from screening and diagnosis to treatment and management, and discover the small but powerful community of parents of children with disorders detected by newborn screening.

**Welcome Reception**
Sunday, October 16 | 5:00–6:30 pm
Let loose, reunite with old friends or meet up with new colleagues, and visit with our industry partners over drinks and hors d’oeuvres.

**Meet the Manufacturers**
Monday, October 17 | 6:00–6:30 pm
Light-hearted presentations from our industry partners Baebies and PerkinElmer.

**Innovate! Sessions**
Tuesday, October 18 | 7:00–8:00 am
Connect with your industry partners and learn of new technologies and services.

**Special Session**
The Next Frontier of Genetics and Privacy: NBS at the Intersection
Tuesday, October 18 | 6:00–7:15 pm

**Awards Ceremony Lunch**
Wednesday, October 19 | 12:00–1:30 pm
Applaud your colleagues and celebrate their achievements over lunch.
APHL 2022 Newborn Screening Symposium Planning Committee

Chair: John Thompson, PhD, MPH, MPA, Washington State Public Health Laboratory
Susan Berry, MD, University of Minnesota
James Bonham, PhD, International Society of Neonatal Screening
Michele Caggana, ScD, FACMG, Wadsworth Center, New York State Department of Health
Christen Crews, MSN, RN, Virginia Department of Health
Carla Cuthbert, PhD, FCCMG, FACMG, Centers for Disease Control and Prevention
Lorrie Folmar, RN, BSN, Alaska Division of Public Health
Aaron Goldenberg, PhD, MPH, Case Western Reserve University
Kim Hart, MS, LCGC, Utah Department of Health and Human Services
Alisha Keehn, MPA, Health Resources and Services Administration
Kelly Kramer, MPH, Washington State Public Health Laboratory
Michelle M. Mills, MSFS, Kansas Department of Health and Environment
Richard Olney, MD, MPH, California Department of Public Health
Ashleigh Ragsdale, MPH, Washington State Public Health Laboratory
Brendan Reilly, BS, Texas Department of State Health Services
Peter Schielen, PhD, International Society for Neonatal Screening
Lisa M. Shook, MA, MCHES, Cincinnati Children’s Hospital Medical Center
Graham Sinclair, PhD, British Columbia Children’s Hospital
Aranjeet Singh, MA, MCHES, Washington State Public Health Laboratory
Angelica Watkins, Washington State Public Health Laboratory
Sainan Wei, MD, PhD, FACMGG, University of Kentucky College of Medicine

Save the Dates for 2023!

October 15–19, 2023

Joint APHL 2023 Newborn Screening Symposium and the International Society for Neonatal Screening Meeting

Sacramento, CA
Agenda of Events
All listed times are Pacific Standard Time (PST).

Sunday, October 16

2:00 pm – 6:30 pm  Registration
3rd Floor Lobby

4:00 pm – 4:15 pm  Welcome
Ballroom A/D

John Thompson, PhD, MPH, MPA, Washington State Public Health Laboratory
Jelili Ojodu, MPH, Association of Public Health Laboratories

4:15 pm – 6:00 pm  Parent/Patient Panel
Ballroom A/D

Moderators:
• Angelica Watkins, Washington State Public Health
• Lani Culley, MPH, Washington State Department of Health Laboratory

Speakers: (Families to be determined)

5:00 pm – 6:30 pm  Welcome Reception
Exhibit Hall
Visit the exhibits and posters

5:30 pm – 6:00 pm  Poster authors P–1 to P–40 available
Exhibit Hall
to discuss their posters.

Monday, October 17

6:30 am – 6:00 pm  Registration
3rd Floor Lobby

6:30 am – 7:30 am  Coffee
3rd Floor Lobby
Room 315

Exploration of Privacy-Enhancing Technologies to Ensure Patient Trust, Privacy, and Data Transparency in CDC ED3N

Amy Gaviglio, MS, CGC, Connetics Consulting/CDC/APHL

This roundtable will review relevant privacy enhancing technologies (PETs), caveats of use, and areas for future research and development. Of particular focus will be privacy-preserving record linkage, a technique to link data from the same patient across different sources in a way that does not compromise personally identifiable information (PII). PPRL can accelerate data sharing by minimizing the manual and labor-intensive processes common in healthcare. Lastly, the roundtable will describe efforts to deploy PETs as part of the Newborn Screening and Molecular Biology Branch’s (NSMBB) Enhancing Data-driven Disease Detection in Newborns (ED3N) platform. Integration of PETs into ED3N will help NBS programs harmonize and analyze their data in a responsible, reproducible manner.

Room 316

What Does Long-Term Follow-up Mean to You? A Discussion With State NBS Programs

Jennifer Taylor, PhD, American College of Medical Genetics and Genomics

Over 20,000 newborns are diagnosed each year with a congenital condition through the newborn screening (NBS) system. The majority of these conditions require life-long care and management, ideally with the care coordinated through a medical home, to assure the best possible outcomes for each diagnosed baby. All stakeholders in the NBS community play important roles in long-term follow-up (LTFU), but there is no national system of LTFU data collection, analysis, sharing, and reporting. In addition, LTFU activities, policies, and practices vary across state NBS programs. This roundtable will provide state NBS programs a forum to discuss their involvement in LTFU and to create a series of definitions of LTFU for each stakeholder group. A new initiative will also be described to capitalize on clinical care efforts to deliver LTFU into a centralized resource that will improve the insight of the benefits of NBS.

Room 317

A Community of Practice: Exploring Current Newborn Screening Result Communication Practices

Brianne Miller, MPH, Children’s National Hospital

This roundtable presentation will provide important preliminary data on parents’ experiences receiving initial newborn screening NBS results as revealed in survey responses from the current National Institute of Health (NIH) funded R01 project which asked parents of a child that received a false positive or normal initial NBS result about their communication experience. It will also create an opportunity for necessary information sharing and collaboration to improve these experiences moving forward with a goal to promote sharing of processes and procedures as well as successes and challenges between NBS program leadership and staff.
7:30 am – 9:00 am  
Coffee
Ballroom Prefunction

8:00 am – 8:30 am  
Break

8:30 am – 10:00 am  
Plenary Session
Ballroom A/D
588-852-22 • 1.5 contact hours for this session

Financial, Legal, Ethical, Policy and Social Implications (FLEPSI)

Moderators:
- Aaron Goldeberg, PhD, MPH, Case Western Reserve University
- Kim Hart, MS, LCGC Utah Department of Health and Human Services

The State of Newborn Screening Systems in the United States in 2021–2022
Sikha Singh, MHS, PMP, Association of Public Health Laboratories

Newborn Screening Modernization: Issues and Strategies
Don Bailey, PhD, RTI International

Development of a Biobank to Support Research for Current and Future Newborn Screening Disease Targets in Canada
Monica Lamoureux, MSc, PMP, CCRP, Children’s Hospital of Eastern Ontario

Newborn Screening Research and Consent — A Review of the Current Landscape in the United States
Shibani Kanungo, MD, MPH, FAAP, FACMG, University of Western Michigan

Counting Conditions on Newborn Screening Panels: Not as Easy as 1, 2, 3
Susan Tanksley, PhD, Texas Department of State Health Services

This session will describe the landscape of newborn screening (NBS) in 2021 through present day and consider the challenges and opportunities now facing NBS programs. Such challenges and opportunities include establishing a biobank to support further understanding of NBS diseases; increasing knowledge and transparency about NBS processes to alleviate concerns; and developing a proposal for harmonizing how conditions are counted and named.

10:00 am – 4:00 pm  
Exhibit and Poster Hall Open

Exhibit Hall

10:00 am – 11:00 am  
Break in the Exhibit Hall

sponsored by Waters Integrated Software Solutions
11:00 am – 12:30 pm  Keynote Session
Ballroom A/D
588-853-22 • 1.5 contact hours for this session

Improvements to Technology, Testing and Treatments: Progressing Towards Universality in Newborn Screening

Moderators:
• John Thompson, PhD, MPH, MPA, Washington State Public Health Laboratory
• Michele Caggana, ScD, FACMG, Wadsworth Center, New York Department of Health

The Future of Public Health, Challenges and Lessons Learned
Umair A. Shah, MD, MPH, Secretary of Health, Washington State Department of Health

Emerging Therapeutic Platforms for Monogenic Disease and Implications for Newborn Screening
Philip J. (P.J.) Brooks, PhD, National Institutes of Health

Improving Access to Care in Sickle Cell Disease
Julie Kanter, MD, The University of Alabama at Birmingham

Assumptions, Access and Adults
Sandra Sirrs, MD, University of British Columbia

This session will focus on promoting equitable access to gene therapies and follow-up care for rare diseases, with the recognition that trust in public health systems has changed in recent years. Discussions will evaluate where the public health system currently stands in increasing access and equity in the care and treatment of rare diseases and how a lack of trust in underserved populations affects the social contract that newborn screening (NBS) programs and other public health systems rely on to function.

12:30 pm – 2:00 pm  Lunch (on your own)

2:00 pm – 3:30 pm  Plenary Session
Ballroom A/D
588-854-22 • 1.5 contact hours for this session

Health Equity

Moderators:
• Michelle Mills, MSFS, Kansas Department of Health and Environment
• Carla Cuthbert, PhD, FCCMG, FACMG, Centers for Disease Control and Prevention

Using NewSTEPs Data to Assess Disparities in Newborn Screening
Amy Gaviglio, MS, CGC, Connetics Consulting/CDC/APHL
Building Relationships to Reduce the Gaps: How Analysis of LFU Data Led to Newfound Partnerships, a More Comprehensive Educational Program, and Increased Equity Within Program Activities
Drew Duncan, MA, Kansas Department of Health

Towards Equity and Timeliness in Cystic Fibrosis Newborn Screening
Albert Faro, MD, Cystic Fibrosis Foundation

Strength of Nation
Socia Love-Thurman, MD, Seattle Indian Health Board

This session will examine equity and disparity as it relates to the newborn screening (NBS) system by assessing whether the universality of NBS is maintained, and potential risk factors identified, through the screening and follow-up process. The session will also focus on the screening of cystic fibrosis (CF) and how to best address disparities in order to counter barriers to timeliness and equity. A discussion on the clinical perspective of health equity based on the experience of treating patients who have been traditionally marginalized will be had.

3:30 pm – 4:00 pm Break in the Exhibit Hall
Exhibit Hall Visit the exhibits and posters

4:00 pm – 5:30 pm Plenary Session
Ballroom A/D

588-855-22 • 1.5 contact hours for this session

Short-term and Long-term Follow-up

Moderators:
• Christen Crews, MSN, RN, Virginia Department of Health
• Kelly Kramer, MPH, Washington State Public Health Laboratory

Putting Families First: Innovative Approaches of Long-Term Follow-up Cares and Check Initiative (LTFU-Cares & Check)
Kee Chan, PhD, American College of Medical Genetics and Genomics

Pilot Project to Reconnect Michigan’s Lost to Follow-up Phenylketonuria Population with Information and Services
Kristy Karasinski, MPH, Michigan Department of Health & Human Services

The Forest or the Trees: 12 years’ Experience of CF, CRMS and Diagnostic Transitions Following Newborn Screening for CF in California
Stanley Sciortino, MPH, PhD, California Department of Public Health

Initial Success of the NewSTEPs Follow-up Learning Exchange (FLEX) Program
Erin Darby, MPH, MCHES, Association of Public Health Laboratories
This session will explore ways that newborn screening (NBS) programs are improving follow-up practices and creating better tools for communicating. It will discuss efforts to put families impacted by spinal muscular atrophy (SMA) first in the design of long-term follow-up (LTFU) tools; summarize ways to connect individuals with phenylketonuria lost to follow-up with services; compare cystic fibrosis (CF) and CF-Related Metabolic Syndrome (CRMS) patients; and describe the structure and value of a peer-to-peer learning exchange program for NBS short-term follow-up (STFU) programs.

6:00 pm – 6:30 pm
Meet the Manufacturers
Exhibit Hall A

Meet the Manufacturers
Light-hearted presentations from Baebies and PerkinElmer, along with snacks and beverages. (not a meal)

Tuesday October 18

6:30 am – 6:00 pm
Registration
3rd Floor Lobby

6:30 am – 7:30 am
Coffee and Light Breakfast
3rd Floor Hallway

7:00 am – 8:00 am
Innovate! Sessions
Room 315 • PerkinElmer
Room 316 • Waters Integrated Software Solutions
See page 17 for session details.

7:30 am – 9:00 am
Coffee
Ballroom Prefunction

8:00 am – 8:30 am
Break

8:30 am – 10:00 am
Plenary Session
Ballroom A/D
588-856-22 • 1.5 contact hours for this session

International Perspectives
Moderators:
• Joanne Mei, PhD, Centers for Disease Control and Prevention
• M. Christine Dorley, PhD, MT(ASCP), Tennessee Department of Health, Laboratory Services
Expanded Neonatal Bloodspot Screening Programmes: A Framework to Prioritize New Conditions With Stakeholders
Marleen Jansen, PhD, Dutch National Institute for Public Health and the Environment

Performance Evaluation of Latin America Laboratories in the CDC Newborn Screening Quality Assurance Programs, 2016–2022
Ernesto Gonzalez Reyes, PhD, Centers for Disease Control and Prevention

Evaluation of the First Year of Screening for MPS I in The Netherlands
Rose Maase, PhD, (ASCP)CM, MRSC, Dutch National Institute for Public Health and the Environment

Evaluating the Use of Whole Genome Sequencing in Newborn Screening: The Genomics England Newborn Genomes Programme
David Bick, MD, Genomics England

**Innovate! Sessions**
Tuesday, October 18, 7:00 am – 8:00 am

**Unique Approaches in Detecting Congenital Cytomegalovirus in DBS**
PerkinElmer
Room 315
Stephanie Dallaire, Senior Manager R&D, PerkinElmer

*In this Innovate! session, the importance of real-time PCR in universal congenital cytomegalovirus using dried blood spots will be discussed.*

**Multiplexed LC-MS/MS Proteomic Methods for Newborn Screening of Wilson Disease and Inborn Errors of Immunity**
Waters Corporation
Room 316
Christopher J. Collins, Chief Technology Officer, Key Proteo

*While NBS is considered an extremely successful public health program in identifying infants with treatable disorders for early intervention, many congenital disorders with highly effective treatments have no specific metabolic biomarkers nor any analytical methods suitable for population screening. In metabolic disorders, the causative mutation often result in reduction or absence of their associated proteins. In these cases, direct measurements of target proteins using multiplexed proteomic LC-MS/MS methods from dried blood spots can be diagnostic and appropriate population screening. This talk will detail the development, testing and validation of a kit-based assay of proteomic newborn screening suitable for use in public health laboratories.*
This session will examine newborn screening (NBS) systems with an international lens, in particular how NBS programs in the Netherlands expanded from 17 to 31 conditions — with an emphasis on improving timeliness and avoiding future false positives while screening Mucopolysaccharidosis type I (MPS I), the performance of Latin American labs participating in the Newborn Screening Quality Assurance Program (NSQAP), and the recent implementation of whole genome sequencing in the United Kingdom.

10:00 am – 10:30 am
Poster Speed Dating
See list of posters and presenters on pages 19–20.

10:00 am – 4:00 pm
Exhibit and Poster Hall Open

10:30 am – 11:00 am
Break in the Exhibit Hall
sponsored by Waters Integrated Software Solutions

11:00 am – 12:30 pm
Plenary Session

Current Recommended Uniform Screening Panel (RUSP) Conditions to State NBS Panels

Moderators:
• Graham Sinclair, PhD, British Columbia Children’s Hospital
• Denise Kay, PhD, Wadsworth Center, New York State Department of Health

Congenital Hypothyroidism Detection in Texas: A Ginormous Study of T4 and TSH as Primary Analyte
Brendan Reilly, BS, Texas Department of State Health Services

Multiplexing Homocysteine into FIA-MS/MS Primary-Tier Screening with Amino Acids, Acylcarnitines, Succinylacetone, Adenosine, Deoxyadenosine and Other Biomarkers by Selective Homocysteine Derivatization
Austin Pickens, PhD, Centers for Disease Control and Prevention

Michigan’s Experience Transitioning from Digital Microfluidics to MS/MS for Lysosomal Storage Disorder Screening
Shawn Moloney, MPH, MLS(ASCP), Michigan Newborn Screening Laboratory

LDT Implementation for the Screening of X-ALD, Pompe Disease and MPS-I with One Dried Blood Spot Using LC-MS/MS
Nicolas Szabo, PhD, Utah Public Health Laboratory
Poster Speed Dating
Tuesday, October 18, 10:00 am – 10:30 am

This session will include short presentations of the following select posters. The full posters may be seen in the exhibit hall.

Moderator: Amy Gaviglio, MS, CGC, Connetics Consulting/CDC/APHL

P–1: Electronic Data Sharing Activities for Newborn Screening Programs
Craig Newman, Altarum

P–2: The Potential for Newborn Screening to Transform Disease Understanding Through Data Retention and Sharing
Amy Brower, American College of Medical Genetics and Genomics

P–6: Early Functional Vision Screening in the Neonatal Intensive Care Unit: What Can It Tell Us?
Catherine Smyth, Anchor Center for Blind Children

P–23: Utilization of Machine Learning in the Newborn Screening Process and Incorporation into CDC ED3N Platform
Clare Grazal, Centers for Disease Control and Prevention

P–3: ELSI Advantage: A Resource for the NBS Community to Facilitate Inclusion of ELSI in Newborn Screening Research
Caroline Lumpkins, American College of Medical Genetics and Genomics

P–28: Creating a Model for Collaborating Around New Conditions in Newborn Screening: A Congenital Cytomegalovirus and Newborn Screening Work Group
Natasha Bonhomme, Expecting Health at Genetic Alliance

P–30: What Has Been the Impact of a 17–year Comprehensive NBS Program in Mexico?
Hector Cruz–Camino, Genomi–k

P–40: Developing and Updating the ACMG ACTion (ACT) Sheets and Algorithms
Megan Lyon, National Coordinating Center for Regional Genetics Networks

P–4: Data Science and Autism: Exploring the Use of Newborn Screening Data to Understand Genetics and Clinical Outcomes
Zohreh Talebizadeh, American College of Medical Genetics and Genomics
P–44: Validation of a Two-tier Testing Algorithm for the Screening of X-linked Adrenoleukodystrophy — The New Jersey Experience
Victoria Floriani, New Jersey Newborn Screening Laboratory

P–54: Improving Long-term Follow-up (LTFU) in a Newborn Screening (NBS) Program
Jennifer Baysinger, Oklahoma State Department of Health

P–5: Celebrating a Decade of Conversations to Facilitate Newborn Screening Pilots: NBSTRN National NBS Pilot Monthly Webinar
Jennifer Taylor, American College of Medical Genetics and Genomics

P–62: Future Collaboration Between Early Intervention and Newborn Screening
Elizabeth Reynolds, RTI International

P–66: Implementation of Weekday Courier Service for Newborn Screening Specimens
Elizabeth Bair, South Carolina Department of Health & Environmental Control

John Leavitt, Texas Department of State Health Services

P–69: Newborn Screening for Severe Combined Immunodeficiency in Texas Using Multiple of the Median
Derek Seidel, Texas Department of State Health Services

P–5a: What Does NBS Research Mean to You? Stories from the NBSTRN SPOTlight Podcast
Kee Chan, PhD, American College of Medical Genetics and Genomics

P–81: Measurement of Non-reducing Terminal Glycosaminoglycan Fragment Increases Specificity of Second-Tier Testing for Mucopolysaccharidosis Type I (MPS I)
Sara Smith, PerkinElmer Genomics

P–70: The Utility of a Five-Spot Punch in Hemoglobinopathy and SCID Testing to Investigate Inconsistent Results and the Educational Outreach
Amy Schlabach, Texas Department of State Health Services
Neonatal Screening for Peroxisomal Disorders: New and Novel Lipid Biomarkers
Enzo Ranieri, PHD, Women’s and Children’s Hospital, Australia

This session will examine how newborn screening (NBS) programs have created efficiencies in testing conditions on the RUSP. Examples include identifying optimal screening procedures for detecting infants with Primary Congenital Hypothyroidism (CH), presenting breakthrough methods for multiplexing total homocysteine (tHcy), examining ways to reduce the number of false positives and improve turn around time (TAT), analyzing how lysosomal storage disorders (LSDs) can benefit from NBS and determine ways metabolomics can be used as a tool in the expansion of screening for new disorders.

12:30 pm – 2:00 pm  Lunch in the Exhibit Hall
Exhibit Hall
Visit the exhibits and posters

1:00 pm – 1:30 pm  Poster authors P–41 to P–81 available to discuss their posters.
Exhibit Hall

2:00 pm – 3:30 pm  Plenary Session
Ballroom A/D

588-858-22 • 1.5 contact hours for this session

Quality Improvement, Quality Control and Quality Assurance
Moderators:
• Lorrie Folmar, RN, BSN, Alaska Division of Public Health
• Lisa Shook, MA, MCHES, Cincinnati Children’s Hospital Medical Center

Using Systems Design Thinking to Improve Internal Notifications Between Laboratory and Follow-up Components of the Kansas Newborn Screening Program, Part 1: Understanding the Current System, User Needs and Improvement Measures
Kinsey Anderson, MPH, Kansas Department of Health and Environment

A Quality Management Project with Inherited Metabolic Disorders Specialty Care Centers to Reduce Referrals Lost to Follow-up
Kathy Chou, PhD, New York State Department of Health

Development of Post-analytical Methodologies for the Uniform Interpretation of Newborn Screening Data
Nicolas Szabo, PhD, Utah Public Health Laboratory

Beyond the Fax Machine: Improving Operations and Communication between Follow-up, NBS Laboratory and NICU
Christen Crews, MSN, RN, Virginia Department of Health

Newborn Screening Follow-up Harmonization Project
Lani Culley, MPH, Washington Public Health Laboratories
This session will provide an overview of practices performed by newborn screening (NBS) programs to improve the quality of their programs. Presentations will include a review of tools used to facilitate virtual collaboration, updates on cases previously closed as Lost to Follow-up, a look into the development of harmonization frameworks, an examination of processes to improve communication, increase timeliness, and reduce the risk of human error, and share ways to streamline efforts between the lab, follow-up and external partners.

3:30 pm – 4:00 pm
Break in the Exhibit Hall
Visit the exhibits and posters

4:00 pm – 5:30 pm
Plenary Session
Ballroom A/D

588-859-22 • 1.5 contact hours for this session

Training, Education and Communication

Moderators:
- Sarah Viall, MSN, PPCNP-BC, Oregon Health & Science University
- Carol Johnson, University of Iowa Hospitals and Clinics

Understanding Clinician Needs and Preferences with Respect to Returned NBS Results
Nicole Ruiz-Schultz, PhD, Utah Public Health Laboratory

Discrepancies between Parent-reported and Known NBS Results: Examining Parent Experiences with Qualitative Interviews
Anne Atkins, MPH, Children’s National Hospital

Engaging Family Leaders in the NBS System
Marianna Raia, MS, CGC, Expecting Health at Genetic Alliance

Developing an Integrated, Mixed-Methods Parent Engagement Research Program: The ScreenPlus ELSI Studies
Aaron Goldenberg, PhD, MPH, Case Western Reserve University

This session will explore the various ways newborn screening (NBS) programs interact with parents and families throughout the screening process. Presentations will explore how programs communicate with communities, and the frustrations and limitations that can occur. Ideas on ways to improve processes from interviews with parents will also be discussed. In order for families to become leaders in the NBS system, adequate training strategies are required to improve confidence and agency. Exploring this parent perspective is integral to creating a public health system that works for everyone.
6:00 pm – 7:30 pm Special Session
Ballroom A/D

The Next Frontier of Genetics and Privacy: NBS at the Intersection

Moderators:
• Amy Gaviglio, MS, CGC, Connetics Consulting/CDC/APHL
• Aaron Goldenberg, PhD, MPH, Case Western Reserve University

Speakers:
• Wendy Benson, MBA, Rady Children’s Institute for Genomic Medicine
• Rachel Lee, PhD HCLD, Texas Department of State Health Services
• Natalie Ram, JD, University of Maryland Carey School of Law

This session will feature presentations focused on genetic privacy in the context of new developments in rapid whole genome sequencing of newborns. Discussions will highlight a private industry perspective (presenting research efforts on rapid whole genome sequencing for rare disease diagnosis in newborns), a state perspective (the aftermath of a court ruling on the Texas NBS program’s storage and use of residual dried blood spots) and a legal perspective (the landscape of policies, regulations and statutes, or their absence, across state NBS programs governing access to residual dried blood spots and for what purposes).

Wednesday, October 19

6:30 am – 6:00 pm Registration
3rd Floor Lobby

6:30 am – 7:30 am Coffee
3rd Floor Lobby

7:00 am – 8:00 am Concurrent Roundtables
Room 315

Hemoglobinopathy Newborn Screening: Is It Time to Increase Molecular Testing?
Amanda Ingram, RN, Tennessee Department of Health

Every Newborn Screening (NBS) program in the US and its territories assesses for hemoglobinopathies utilizing isoelectric focusing electrophoresis (IEF) and/or High-Performance Liquid Chromatography (HPLC) techniques. While these methods are robust, in several instances molecular methods become necessary to precisely identify the hemoglobin variant or thalassemia genotype. Currently, the number of
state and territorial NBS programs that have access to molecular testing as well as the methodologies they used were determined through a nationwide survey of these programs. This roundtable will discuss the results of a survey conducted in 2018 of all US state newborn screening programs to determine approaches used for detecting and reporting beta-thalassemia and whether states used molecular methods in their testing algorithm.

Room 316

**Embracing Expanded COVID-era Capabilities in Metabolic Newborn Screening (NBS) Follow-up in Oregon**

Sarah Viall, MSN, PPCNP-BC, Oregon Health Sciences University
Leah Wessenberg, FNP, MN, Oregon Health Sciences University

This roundtable will review how the Metabolic Genetics Clinic adjusted to changes as a result of the COVID-19 pandemic. Discussion will include how they altered workflows in unprecedented ways to provide uninterrupted expedient follow-up of potentially affected babies while expanding remote collaboration with newborn screening (NBS) program staff, rolling out telemedicine visits, adding contiguous state licenses and coordinating community follow-up diagnostic test collection and treatment. Ultimately, as the public health crisis enters a new phase, the follow-up program has been able to leverage many of capabilities resulting in a more flexible experience for families and other stakeholders, including expanding remote collaboration, virtual education and telemedicine visits.

Room 317

**Good, Better, Best: Setting a Standard for the Newborn Screening Workforce of Today, Tomorrow and the Future**

Susan Tanksley, PhD, Texas Department of State Health Services

The roundtable session will engage participants in robust discussion on the outcomes of a survey aimed at identifying newborn screening (NBS) services and activities that are currently being conducted by state NBS programs and give input on next steps to develop guidance on standards for staffing a NBS program. Participants will be asked to break out into groups between various programs and explore a series of questions focusing on aspects of staffing components that make an effective NBS program. Roundtable outcomes will inform existing and future efforts to advance understanding of NBS programs’ needs and potential solutions to addressing workforce challenges.

**Schedule**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am – 9:00 am</td>
<td>Coffee</td>
</tr>
<tr>
<td>8:00 am – 8:30 am</td>
<td>Break</td>
</tr>
</tbody>
</table>
8:30 am – 10:00 am  
**Plenary Session**

**Ballroom A/D**

588-860-22 • 1.5 contact hours for this session

**Data Analytics and Bioinformatics**

Moderators:

- Charles Lechner, MS, Tennessee Department of Health: Laboratory Services
- Christian Alcorta, MS, Virginia Division of Consolidated Laboratory Services

Creating a National Newborn Screening Bioinformatics and Variant Interpretation Tool: LIMS Lite and ED3N

Amy Gaviglio, MS, CGC, Connetics Consulting/CDC/APHL

Benefits and Burdens of Gene Variant Analysis in the Newborn Screening Setting

Denise Kay, PhD, Wadsworth Center, New York State Department of Health

Creation of a Variant Analysis Pipeline for Texas Newborn Screening DNA Sequencing

Samantha Marcellus, MPH, Texas Department of State Health Services

This session will evaluate how data analytics and bioinformatics can help address challenges and create opportunities for newborn screening (NBS) programs. Presentations will include a description of the efforts made to simplify the addition of next generation sequencing within NBS programs, ways in which a database can facilitate and streamline variant data collection, interpretation and reporting, and an overview of current recommendations and practices for sequencing and variant classification.

10:00 am – 4:00 pm  
**Exhibit and Poster Hall Open**

Exhibit Hall

10:00 am – 10:30 am  
**Break in the Exhibit Hall**

Visit the exhibits and posters

10:30 am – 12:00 pm  
**Plenary Session**

**Ballroom A/D**

588-861-22 • 1.5 contact hours for this session

**Molecular Technology**

Moderators:

- Suzanne Cordovado, PhD, Centers for Disease Control and Prevention
- Sainan Wei, MD, PhD, Kentucky Division of Laboratory Services

Severe Combined Immunodeficiency (SCID) Screening for Premature Infants Quality Improvement Project

Ruthanne Sheller, MPH, Association of Public Health Laboratories
Molecular Investigation of Idiopathic T-cell Lymphopenia Cases in New York State
Denise Kay, PhD, Wadsworth Center, New York State Department of Health

Expanded Screening for Cystic Fibrosis - No Sweat
Michael Cellucci, MD, Delaware Newborn Screening Program

The p.Y319C GALC Variant and Newborn Screening for Krabbe Disease
Dietrich Matern, MD, PhD, Mayo Clinic

This session will summarize newborn screening (NBS) for various types of conditions to better understand screening outcomes in premature newborns and practices that reduce unnecessary follow-up activities. Conditions include NBS for Severe Combined Immunodeficiency (SCID) by measurement of T-cell receptor excision circles (TRECs), molecular investigation of Idiopathic T-cell Lymphopenia and expanded screening for Cystic Fibrosis (CF) and Krabbe disease.

12:00 pm – 1:30 pm  Awards Ceremony Lunch
Exhibit Hall A
Moderator: Scott Becker, MS, Association of Public Health Laboratories

1:30 pm – 3:00 pm  Plenary Session
Ballroom A/D
588-862-22 • 1.5 contact hours for this session

Health Information Technology (HIT)

Moderators:
• Brendan Reilly, BS, Texas Department of State Health Services
• Stanley Sciortino, MPH, PhD, California Department of Public Health

Promoting Newborn Screening Interoperability — How to Effectively Communicate Benefits to Improve Hospital Engagement
Emily Hopkins, MS, Virginia Division of Consolidated Laboratory Services

Advancing Electronic Data Sharing for Newborn Screening Programs
Craig Newman, PhD, Altarum

Utilizing a Data Exchange to Achieve Interoperability in Newborn Screening
Heather Brand, Minnesota Department of Health Newborn Screening

Improving COOP in South Carolina: Lessons Learned from Memorial Day Weekend 2021
Elizabeth Bair, MS, South Carolina Dept of Health & Environmental Control

This session will evaluate methods of technology used to support newborn screening (NBS) programs including how electronic data exchange can impact hospital engagement, the approaches and tools utilized to help NBS programs better understand and implement their interoperability goals and how to improve future Continuity of Operations Plans (COOP) when faced with technology issues.
3:00 pm – 4:00 pm  Break and Raffle in the Exhibit Hall
Exhibit Hall
Visit the exhibits and posters. Raffle starts at 3:30 pm.

4:00 pm – 5:30 pm  Plenary Session
Ballroom A/D
588-863-22 • 1.5 contact hours for this session

Conditions Under Consideration for Addition to, or Removal from, State NBS Panels

Moderators:
• Mei Baker, MD, FACMG, Wisconsin State Laboratory of Hygiene
• Pranesh Chakraborty, PhD, Newborn Screening Ontario

Clinical Sensitivity of Dried Blood Spots and Saliva for Detection of Congenital Cytomegalovirus Disease
Tatiana Lanzieri, MD, MPH, Centers for Disease Control and Prevention

Evaluation of Testing for Congenital Cytomegalovirus in Dried Blood Spot Using Real-Time PCR in Minnesota
Carrie Wolf, MBS, Minnesota Department of Health

Early Check Newborn Screening Pilot Study for Duchenne and Related Muscular Dystrophies in North Carolina
Holly Peay, PhD, MS, RTI International

Factors Influencing Creatine Kinase-MM Levels in Newborns and the Relevance for Newborn Screening for Duchenne Muscular Dystrophy
Norma Tavakoli, PhD, Wadsworth Center, New York State Department of Health

This session will explore testing for congenital cytomegalovirus (cCMV) and Duchenne Muscular Dystrophy (DMD) in three states. Presenters will discuss the efficiency of CMV dried blood spot (DBS) testing methods, share data from testing dried blood spots using real-time PCR and discuss implementation efforts of testing for CMV in Minnesota. North Carolina will discuss the screening of DMD through the Early Check NBS study, which offers consented screening for conditions currently not a part of routine NBS. New York will evaluate the screening for DMD as part of a pilot study that will help to determine recommendations for states implementing screening.

6:00 pm – 10:00 pm  Off-site Social
Sponsored by PerkinElmer
Thursday, October 20

6:30 am – 12:30 pm  Registration
3rd Floor Lobby

6:30 am – 7:30 am  Coffee
3rd Floor Lobby

7:00 am – 8:00 am  ISNS Membership Meeting
Ballroom A/D

7:30 am – 9:00 am  Coffee
Ballroom Prefunction

8:00 am – 8:30 am  Break

8:30 am – 10:00 am  Plenary Session
Ballroom A/D
588-864-22 • 1.5 contact hours for this session

Adoption and Use of Second-tier Testing

Moderators:
• Ewa King, PhD, Association of Public Health Laboratories
• Joseph Orsini, PhD, New York State Department of Health

The Changing Landscape of Mass Spectrometry-based Biochemical Second-tier Newborn Screening
Kostas Petritis, PhD, Center for Disease Control and Prevention

Newborn Screening for Mucopolysaccharidoses: Evolution and Improvement of a Two-tier Screening Approach
Patricia Hall, PhD, Mayo Clinic

Dual 2nd-tier Screening of Lysosomal Disorders Glycogen Storage Disease Type II (Pompe) and Mucopolysaccharidosis I (MPS I) with Biochemical and Sequencing — A Comparison of Data, Benefits and Outcomes
Michelle Mills, MS, Kansas Department of Health and Environment

Newborn Screening for the Homocystinurias (Classical Homocystinuria and Remethylation Disorders) — Expanding and Improving Biomarkers and Algorithms
Devinder Kaur, PhD, New England Newborn Screening Program

Vitamin B12 Deficiency: Implications for Newborn Screening
Graham Sinclair, PhD, British Columbia Children’s Hospital
This session will evaluate the current state of second-tier screening, the methods used, and the challenges associated with either adopting in-house second-tier screening or sending testing to a reference laboratory. Ways to improve screening performance for Mucopolysaccharidosis Type I (MPSI), lysosomal disorders glycogen storage disease type II (Pompe), homocystinuria (HCU) and HCU-ReMet disorders and vitamin B12 deficiency will be discussed.

10:00 am – 10:30 am  Break
Ballroom Prefunction

10:30 am – 12:00 pm  Plenary Session
Ballroom A/D
588-865-22 • 1.5 contact hours for this session

Pilot Studies

Moderators:
• Aranjeet Singh, MA, MCHES, Washington State Public Health Laboratory
• Susan Berry, MD, University of Minnesota

Reimaging Newborn Screening Pilots: Models, Mining and More
Amy Brower, PhD, American College of Medical Genetics and Genomics

It Takes a System: Implementation of Screening for Pompe Disease, MPS I and Krabbe Disease in Georgia — Pilot Studies, Post-analytical Tools, Second-tier Testing and a Lot of Communication
Patricia Hall, PhD, Mayo Clinic

ScreenPlus: A Pilot Study to Screen for 14 Disorders: Overview, Challenges and Preliminary Results
Joseph Orsini, PhD, Wadsworth Center, New York State Department of Health

Staged Newborn Screening for Common Childhood Diseases — The Combined Antibody Study for Celiac And Diabetes Evaluation (CASCADE Study)
William Hagopian, MD, PhD, University of Washington

This session will explore various pilot studies for newborn screening (NBS). It will reflect on whether the length of a pilot study affects long-term follow-up (LTFU) data, how the amount of time spent on laboratory work is affected when a new pilot study is implemented, how pilot studies provide critical evidence to assess the appropriateness of candidate disorders for population wide NBS and whether early detection of diseases can improve quality of life and result in lower provider and testing costs.

12:00 pm  Symposium Adjourns

12:30 pm – 4:00 pm  Lab Tour

Optional Tour to the Washington State Newborn Screening Laboratory (prior sign-up required)
For decades, Waters and Integrated Software Solutions have independently supported the needs of the newborn screening community, from analytical instrumentation to comprehensive software systems.

We look forward to meeting with you at the 2022 Newborn Screening Symposium, where, as a single corporation, we will be highlighting our entire range of products, including:

- **OMNI-Lab NBS LIMS**: Patient-centric computing solutions for your NBS laboratory
- **RenataDX™ System**: FIA-MS/MS IVD system for high throughput screening
- **MassTrak IVD System solutions**: our latest LC-MS/MS systems for all your Mass Spectrometry requirements

LEARN MORE
Exhibitors and Sponsors

Thank you to our exhibitors and sponsors for their support of the Symposium! Be sure to visit them in the exhibit hall. Details and contact information can be found on pages 34–40.

Gold Circle
Waters Integrated Software Solutions

Silver Circle
Everylife Foundation for Rare Diseases
PerkinElmer

Bronze Circle
Baebies
CLSI
EBF LLC
Expecting Health/Baby’s First Test
Labsystems Diagnostics Oy
Luminex, a DiaSorin company
Quantabio
Sebia

Exhibitors
American College of Medical Genetics and Genomics
Astoria-Pacific
Asuragen, a Bio-Techne brand
Bio-Rad Laboratories
BSD Robotics
Centers for Disease Control and Prevention
GelbChem
HCU Network America
iConnect Consulting
National Coordinating Center for the Regional Genetics Networks
OpenELIS Foundation
STAT Courier Service, Inc.

Exhibit Hall Schedule
October 16–19, 2022

Sunday, October 16
5:00 pm – 6:30 pm  Hall Open
5:00–6:30 pm  Welcome Reception

Monday, October 17
10:00 am – 4:00 pm  Hall Open
10:00–11:00 am  Break
3:30–4:00 pm  Break

Tuesday, October 18
10:00 am – 4:00 pm  Hall Open
10:30–11:00 am  Break
12:30–2:00 pm  Box Lunch
3:30–4:00 pm  Break

Wednesday, October 19
10:00 am – 4:00 pm  Hall Open
10:00–10:30 am  Break
12:00–1:30 pm  Lunch and Awards
3:00–4:00 pm  Break
3:30 pm  Raffle Drawing
The EveryLife Foundation celebrates state laboratories working in partnership with rare disease advocates to ensure that all babies - no matter where they are born - have the benefit of robust and uniform testing for diseases on the RUSP.

Together by 2025 we can ensure that 60 percent of American babies are born in a state that is in line with the RUSP.
Exhibitors by Booth Number

| 101  | NBSTRN/ACMG                        |
| 102  | National Coordinating Center for the Regional Genetics Networks |
| 105  | HCU Network America                |
| 106  | iConnect Consulting                |
| 107  | Luminex, a DiaSorin Company        |
| 108  | EBF LLC                            |
| 109/111 | Waters Integrated Software Solutions |
| 113/115 | Centers for Disease Control and Prevention |
| 201/203/205 | PerkinElmer                     |
| 202  | STAT Courier Service, Inc.         |
| 204  | OpenELIS Foundation                |
| 206  | CLSI                               |
| 207  | BSD Robotics                       |
| 208  | Bio-Rad Laboratories               |
| 301  | Sebia                              |
| 302  | Quantabio                          |
| 303  | Labsystems Diagnostics Oy          |
| 304  | Asuragen, a Bio-Technne brand      |
| 305/307 | Expecting Health/Baby’s First Test |
| 306/308 | Everylife Foundation for Rare Diseases |
| 310/312 | Baebies                           |
| 314  | GelbChem, LLC                      |
| 316  | Astoria-Pacific                    |

Together, we can improve health outcomes for mothers and babies around the world.

VISIT PERKINELMER AT BOOTH 201 TO LEARN MORE

For a complete insight on newborn screening products, services and latest updates, visit our website: https://rh.perkinelmer.com/

Copyright © 2022 PerkinElmer, Inc. All rights reserved. PerkinElmer® is a registered trademark of PerkinElmer, Inc. All other trademarks are the property of their respective owners. AG012208_24A_AD
Astoria-Pacific

15130 SE 82nd, Clackamas, OR 97015
503.657.3010 • www.astoria-pacific.com/spotcheck/

Astoria-Pacific is a small business that is fully dedicated to providing our clients with the best support and applications as possible. We are honored that Newborn Screening Programs rely on us to keep their newborns safe. We offer Laboratory Automation, Diagnostic Reagent Kits, and Reference Materials to neonatal laboratories worldwide.

Asuragen, a Bio-Techne Brand

2150 Woodward St., Suite 100, Austin, TX 78744
512.681.5387 • www.asuragen.com

Asuragen provides best-in-class molecular diagnostic products to improve the way patients are treated in genetics and oncology. Our diagnostic systems, which include proprietary chemistry and software, are designed for use with widely available instruments to ease adoption and quickly expand lab test menus. Our diagnostic tests and companion diagnostic partnerships address current and emerging clinical needs in reproductive health, cancer diagnosis and monitoring and inherited disease.

Baebies

Silver Sustaining Member

25 Alexandria Way, Durham, NC 27703
919.891.0432 • www.baebies.com

Baebies is guided by the vision that “everyone deserves a healthy start.” Our SEEKER® newborn screening platform is CE-marked and authorized by the U.S. FDA to screen four lysosomal storage disorders. Its core technology is driven by digital microfluidics, which allows for shorter testing times using optimized assays and microliter-sized samples. Our innovative products are designed for both central laboratories and point-of-care settings to maximize clinical impact. We’re driven by our mission to save lives and make lives better for all by bringing new technologies, new tests, and new hope to children, adults, and healthcare professionals worldwide.

Bio-Rad Laboratories

Diamond Sustaining Member

4000 Alfred Nobel Dr., Hercules, CA 94547
510.741.1000 • www.bio-rad.com

Bio-Rad Laboratories develops, manufactures, sells, and supports a large portfolio of products for newborn screening and diagnostics. Bio-Rad has been a global leader in thalassemia and sickle cell screening for over 30 years, providing “Gold Standard” automated solutions for newborn programs worldwide. We also offer a suite of market-leading qPCR and digital PCR technologies to support molecular testing.
BSD Robotics
11 Aldinga St., Brendale, QLD 4500 Australia
61.07.3881.1834 • wwwbsdrobotics.com

BSD Robotics is dedicated to the art of semi-automated laboratory instruments for life science applications. Our capabilities include manufacturing, research and development, industrial design, customization and service and support of our portfolio. BSD products are trusted and adopted by leading scientific organizations across the globe. BSD instruments range are designed to increase traceability and throughput, whilst ensuring compliance with validated laboratory protocols.

Centers for Disease Control and Prevention
Booths 113/115

1600 Clifton Rd., Atlanta, GA 30329
770.488.7571 • www.cdc.gov/newbornscreening/

CDC is the nation’s leading science-based, data-driven, service organization that protects the public’s health. For more than 70 years, we’ve put science into action to help children stay healthy so they can grow and learn; to help families, businesses, and communities fight disease and stay strong; and to protect the public’s health.

CLSI
Corporate Colleague Sustaining Member
Booth 206

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit organization that develops medical laboratory standards. CLSI facilitates the creation of best practice standards for medical laboratories by using the expertise of our volunteers. Laboratories and in vitro diagnostic test developers use CLSI standards to improve their testing outcomes, maintain accreditation, bring products to market faster, and navigate regulatory hurdles. We publish standards in 10 specialty areas, including Newborn Screening.

EBF LLC
Booth 108

530 Old Sulphur Springs Rd., Mauldin, SC  29662
800.387.2648 • www.ebf-inc.com

Eastern Business Forms, Inc. has been a leading provider of newborn screening collection devices for more than 50 years. Our goal is to exceed customer requirements by leveraging our extensive manufacturing experience and providing superior customer service. EBF is the exclusive provider of Whatman 903 filter paper in the United States.
Everylife Foundation for Rare Diseases
Booths 306/308
1012 14th St. NW, Suite 500, Washington, DC 20005
202.697.7273 • www.everylifefoundation.org

The EveryLife Foundation for Rare Diseases is a 501(c)(3) nonprofit, nonpartisan organization dedicated to empowering the rare disease patient community to advocate for impactful, science-driven legislation and policy that advances the equitable development of and access to lifesaving diagnoses, treatments and cures.

Expecting Health/ Baby’s First Test
Booths 305/307
26400 Woodfield Rd., #189, Damascus, MD 20872
202.966.5557 • www.expectinghealth.org

Expecting Health provides families with the most current tools and information - from planning a pregnancy to early infant care. Baby’s First Test, an Expecting Health program, provides newborn screening information and resources to more than 300,000 people annually. Our work in newborn screening is to convene stakeholders and experts, connect people to relevant and action-oriented information, and center the experiences of families as we build towards a more inclusive and responsive newborn screening system.

GelbChem LLC
Booth 314
4000 Mason Rd., Fluke Hall, Suite 300, Seattle, WA 98105
206.717.3515 • www.gelbchem.com

GelbChem is driven to supply quality reagents and analytical methodologies to the world of Newborn Screening and diagnostics. A biotech company based in Seattle, GelbChem was conceived in Dr. Michael Gelb’s laboratory at the University of Washington. Backed by a 20-year tradition of innovation in newborn screening and diagnosis of inborn errors of metabolism, GelbChem has risen to meet the global need for novel analytical technologies to support clinical trials, population screens, laboratory research, and more

HCU Network America
Booth 105
15 S. Mallory Ave., Batavia, IL 60510
630.546.6452 • www.hcunetworkamerica.org

The HCU Network America strives to inform and provide resources for patients and families, create connections, influence state and federal policy, and support advancement of diagnosis and treatment for Homocystinuria (HCU) and related disorders. We: support research that improves diagnosis and treatment including a cure for the disease, provide information and resources to better manage the disease, and create connections across the community.
iConnect Consulting
715 32nd St., San Francisco, CA 94121
415.735.5540 • www.iconnectconsulting.com

iConnect Lab Web Portal (LWP) is a secure cloud-based ETOR solution offering
Newborn screening programs an intuitive, real-time platform to order tests, track
progress and receive results. Lab Web Portal is easy to integrate with hospitals,
health information exchanges, laboratory information systems and to share results
with PCPs.

Labsystems Diagnostics Oy
Tiilitie 3, Vantaa 01720 Finland
832.4686023 • www.labsystemsdx.com

Labsystems Diagnostics Oy, Finland has been developing, manufacturing and
distributing innovative products for newborn screening for over 3 decades. We cover
the entire range of methods for newborn screening and offer complete solutions
including automation and software options. We distribute our products to over
70 countries worldwide and all our processes and products are CE IVD certified.
Cooperation and studies in customer laboratories enable us to independently test our
products under real conditions.

Luminex, a DiaSorin Company/
DiaSorin Molecular
Gold Sustaining Member
12212 Technology Blvd., Austin, TX 78727
888.219.8020 • www.diasorin.com

We are a unique combination of specialists for your infectious disease molecular testing
needs. For decades, we have developed and produced sample-to-answer molecular
diagnostic solutions for clinical labs, worldwide. Our tests for women’s health,
encephalitis, and neonatal testing are scalable and flexible for any size laboratory.

National Coordinating Center for
the Regional Genetics Networks
7101 Wisconsin Ave., Suite 1101, Bethesda, MD 20814
803.438.8581 • www.nccrcg.org

The National Coordinating Center for the Regional Genetics Networks (NCC), a Health
Resources and Services Administration (HRSA) funded program, has a mission is
to improve access to genetic services for underserved populations. This mission is
accomplished mainly through the development of educational materials, including
the ACMG ACT Sheets. Stop by our booth to learn about the newly updated Metabolic
Conditions ACMG ACT Sheets and Algorithms.
The NBSTRN is a key component of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Hunter Kelly Newborn Screening Research Program. The American College of Medical Genetics and Genomics (ACMG) operates the NBSTRN. Our mission is to facilitate newborn screening research to discover novel technologies, treatments, and interventions through the development of resources, tools, and expertise. We work with researchers, healthcare professionals, parents, families, advocates, and state NBS programs.

The OpenELIS Foundation is a 501(c)(3) nonprofit corporation whose mission is to provide open source software and services to public health laboratories that will meet the demands of today’s responsive public health laboratory. OpenELIS is designed to be an enterprise solution that scales to the needs of any public health laboratory, from small to large, supports multiple laboratory locations, and handles the needs of clinical, environmental, and newborn screening testing within a single system.

PerkinElmer is a global leader committed to innovating for a healthier world. Our dedicated team of about 17,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. Our innovative detection, imaging, informatics and service capabilities, combined with deep market knowledge and expertise, help customers gain earlier and more accurate insights to improve lives and the world around us.

Quantabio is a leading provider of advanced DNA and RNA amplification reagents for the most demanding molecular testing applications in applied, translational, and life
Sebia

Silver Sustaining Member

1705 Corporate Dr., Suite 400, Norcross, GA 30093
800.835.6497 • www.sebia.com

Sebia is a global specialty IVD company focused on protein analysis. The new CAPILLARYS 3 DBS* instrument utilizes Sebia’s proprietary and best-in-class capillary electrophoresis separation technology to maximize resolution for newborn Hemoglobin (Hb) disorder screening and confirmation. By offering NBS labs a fully automated, walkaway platform, Sebia seeks to improve NBS laboratory workflows, freeing up valuable time for labs to focus on value-added tasks. *CAPILLARYS 3 DBS not currently available for sale in the USA.
STAT Courier Service, Inc.
16 Hawk Ridge Dr., Lake St. Louis, MO 63367
888.592.7828 • www.stat-courier.com

STAT Courier Service Inc. connects communities with logistical solutions nationwide to drive better healthcare outcomes for all newborn citizens through medical courier services for newborn screening testing in addition to clinical and environmental specimens and medical supplies.

Waters Integrated Software Solutions
Platinum Sustaining Member
34 Maple St., Milford, MA 01757
800.867.1263 • www.waters.com

Waters mission is to assist your laboratory by unlocking the potential of science. With innovative solutions for Newborn Screening, such as the RenataDX™ FIA-MS/MS System, our leading LC-MS/MS instruments, and OMNI-Lab NBS — our patient-centric, fully-featured LIMS for Newborn Screening, we help you improve the lives of patients around the world.

Want to ensure reliable and consistent delivery of all your Newborn Screening Cards for timely testing?

Come visit us at Booth #202 for more information on how to improve your NBS card delivery process

stat-courier.com
888-592-7828
Posters

Posters may be viewed in-person in the Exhibit Hall during exhibit hall hours on Sunday–Wednesday, October 16–19, and on the online platform during the entire Symposium.

Full poster abstracts may be found on the Symposium website www.aphl.org/nbs2022 or on the mobile app.

* Posters that have been selected to be part of the Poster Speed Dating session on Tuesday, October 18.

P–1*
Electronic Data Sharing Activities for Newborn Screening Programs
C. Newman¹, T. Tolley², T. Abraham¹, C. Lavell¹; ¹Altarum, Jonesboro, GA, ²OZ Systems, Arlington, TX

Presenter: Craig Newman, Altarum, craig.newman@altarum.org

P–2*
The Potential for Newborn Screening to Transform Disease Understanding Through Data Retention and Sharing
A. Brower, K. Chan, J. Taylor, G. Tona, Y. Unnikumaran and L. Barnes, American College of Medical Genetics and Genomics, Bethesda, MD

Presenter: Amy Brower, American College of Medical Genetics and Genomics, abrower@acmg.net

P–3*
ELSI Advantage: A Resource for the NBS Community to Facilitate Inclusion of ELSI in Newborn Screening Research
C. Lumpkins¹, K. Chan¹, E. Goldman², A. Goldenberg³, I. Holm⁴, A. Brower¹; ¹American College of Medical Genetics and Genomics, Bethesda, MD, ²University of Michigan, Lansing, MI, ³Case Western Reserve University, Cleveland, OH, ⁴Harvard Medical School, Boston, MA

Presenter: Caroline Lumpkins, American College of Medical Genetics and Genomics, clumpkins@acmg.net

P–4*
Data Science and Autism: Exploring the Use of Newborn Screening Data to Understand Genetics and Clinical Outcomes
Z. Talebizadeh, C. Lumpkins and A. Brower, American College of Medical Genetics and Genomics, Bethesda, MD

Presenter: Zohreh Talebizadeh, American College of Medical Genetics and Genomics, ztalebizadeh@acmg.net
P–5*
Celebrating a Decade of Conversations to Facilitate Newborn Screening Pilots: NBSTRN National NBS Pilot Monthly Webinar
J. Taylor, K. Chan and A. Brower, American College of Medical Genetics and Genomics, Bethesda, MD

**Presenter:** Jennifer Taylor, American College of Medical Genetics and Genomics, jtaylor@acmg.net

P–5a*
What Does Long-Term Follow-Up Mean to You? A Discussion with State NBS Programs
J. Taylor¹, J. Baysinger², C. Johnson³, A. Burke⁴, J. Hauser⁵, J.A. Bolick⁶, K. Chan³, L. Barnes⁴, Y. Unnikumaran¹, A. Bower¹; ¹American College of Medical Genetics and Genomics, Bethesda, MD, Oklahoma State Department of Health, ²Oklahoma City, OK, ³Iowa Newborn Screening Program, Iowa City, IA, ⁴North Dakota Department of Health, Pierre, ND, ⁵Minnesota Department of Health, St. Paul, MN, ⁶Arkansas Children’s Hospital, Little Rock, AR

**Presenter:** Kee Chan, American College of Medical Genetics and Genomics, kchan@acmg.net

P–6*
Early Functional Vision Screening in the Neonatal Intensive Care Unit: What Can It Tell Us?
R. King¹, C. Smyth²; ¹Children’s Eye Physicians, Centennial, CO, ²Anchor Center for Blind Children, Fort Collins, CO

**Presenters:** Catherine Smyth and Robert King, Anchor Center for Blind Children, csmyth@anchorcenter.org

P–7
California Newborn Screening – Validation of NeoBaseTM2 Assay on QSightTM Systems

**Presenter:** Kumaran Ramanathan, California Department of Health, kumaran.ramanathan@cdph.ca.gov
P–8
Pompe Disease Newborn Screening in California After Four Years

Presenter: Jamie Matteson, California Department of Public Health, jamie.matteson@cdph.ca.gov

P–9
An Epidemiological Approach to Setting and Monitoring Cutoffs for a New Mass Spectrometry Screening Assay
J. Matteson, H. Tang, K. Ramanathan, P. Neogi, T. Bishops and S. Sciortino, California Department of Public Health, Richmond, CA

Presenter: Jamie Matteson, California Department of Public Health, jamie.matteson@cdph.ca.gov

P–10
Freeze/Thaw Stability of 17OHP, T4, TGal and TSH Analytes in Dried Blood Spots
C. Brown, G. Pena, E. McCown, J. Mei and P. Petritis, Centers for Disease Control and Prevention, Atlanta, GA

Presenter: Christofer Brown, Centers for Disease Control and Prevention, qhk3@cdc.gov

P–11
Multiplexing Iduronate 2-Sulphatase (for MPSII) with the LSD 6-Plex Assay Using Cold-Induced Aqueous Acetonitrile Phase Separation
E. Courtney, A. Pickens, C. Cuthbert and K. Petritis, Centers for Disease Control and Prevention, Atlanta, GA

Presenter: Elya Courtney, Centers for Disease Control and Prevention, pli3@cdc.gov

P–12
Development of Spinal Muscular Atrophy Proficiency Testing and Quality Control Programs
C. Greene, K. Greene, A. McCabe, F. Lee, S. Cordovado and C. Cuthbert, Centers for Disease Control and Prevention, Atlanta, GA

Presenter: Chris Greene, Centers for Disease Control and Prevention, crg0@cdc.gov
P–13
The NBS Molecular Training Workshop
L. Hancock¹, C. Saavedra-Matiz², R. Lee³, G. Zarbalian⁴, O. Akinsola⁴, J. Ojodu⁴, C. Cuthbert¹, S. Cordovado¹; ¹Centers for Disease Control and Prevention, Atlanta, GA, ²Wadsworth Center, New York State Department of Health, Albany, NY, ³Texas Department of State Health Services, Austin, TX, ⁴Association of Public Health Laboratories, Silver Spring, MD
Presenter: Laura Hancock, Centers for Disease Control and Prevention, Ifn2@cdc.gov

P–14
Development of QC and PT Dried Blood Spot-based Quality Assurance Materials for Second-tier LC-MS/MS Methods
M. Kilgore, T. Lim, S. Isenberg, C. Cuthbert and K. Petritis, Centers for Disease Control and Prevention, Atlanta, GA
Presenter: Timothy Lim, Centers for Disease Control and Prevention, tlim@cdc.gov

P–15
Review of C14.1 Cutoffs for Newborn Screening-targeted Very-long-chain Acyl-CoA Dehydrogenase Deficiency (VLCADD)
A. Brar¹, P. Chakraborty²; ¹Children’s Hospital of Eastern Ontario, Ottawa, ON, Canada, ²Newborn Screening Ontario, Ottawa, ON, Canada
Presenter: Monica Lamoureux, Newborn Screening Ontario, molamoureux@cheo.on.ca

P–16
Francis Lee, C. Greene, A. McCabe, A. Moseley, C. Cuthbert and S. Cordovado, Centers for Disease Control and Prevention, Atlanta, GA
Presenter: Francis Lee, Centers for Disease Control and Prevention, icr0@cdc.gov

P–17
Development of Dried Blood Spot (DBS) Proficiency Testing Materials for Guanidinoacetate Methyltransferase Deficiency and Lysosomal Storage Disorders
T. Lim, M. Kilgore, S. Isenberg and K. Petritis, Centers for Disease Control & Prevention, Atlanta, GA
Presenter: Timothy Lim, Centers for Disease Control & Prevention, tlim@cdc.gov
P–18
Development of a Nine-level Dried Blood Spot-based Linearity Material Panel for 43 Newborn Screening Biomarkers
T. Lim, E. Lobo, M. Kilgore, A. Pickens, S. Isenberg, and K. Petritis, Centers for Disease Control and Prevention, Atlanta, GA
Presenter: Timothy Lim, Centers for Disease Control & Prevention, tlim@cdc.gov

P–19
Investigating Strategies for Overcoming the Challenges of Low and Non-homogeneous Biotinidase Activity in Dried Blood Spot Based QA Specimens
E. McCown and K. Petritis, Centers for Disease Control and Prevention, Atlanta, GA
Presenter: Elizabeth McCown, Centers for Disease Control and Prevention, erm5@cdc.gov

P–20
Effect of Methanol Quenching on Newborn Screening for Succinylacetone Analysis in Dried Blood Spots
D. Peppers, A. Pickens, C. Cuthbert and K. Petritis, Centers for Disease Control and Prevention, Atlanta, GA
Presenter: Daquille Peppers, Centers for Disease Control and Prevention, syy7@cdc.gov

P–21
Health Economic Evaluation and pan-Canadian Collaboration for Spinal Muscular Atrophy (SMA) Newborn Screening
A. Wyatt1, P. Chakraborty2; 1Children Hospital of Eastern Ontario, Ottawa, ON, Canada, 2Newborn Screening Ontario, Ottawa, ON, Canada
Presenter: Pranesh Chakraborty, Newborn Screening Ontario, pchakraborty@cheo.on.ca

P–22
Pivoting to Telegenetics for Sickle Cell Trait Newborn Screening Counseling and Education
L. Shook, D. Haygood, C. Mosley and C. Quinn, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Presenter: Lisa Shook, Cincinnati Children’s Hospital Medical Center, lisa.shook@cchmc.org
P–23
Utilization of Machine Learning in the Newborn Screening Process and Incorporation into CDC ED3N Platform
C. Grazal¹, E. McAuley², A. Gaviglio³, C. Cuthbert⁴, B. Scott¹, A. Chiang¹; ¹Booz Allen Hamilton/CDC, Atlanta, GA, ²ES/CDC, Minneapolis, MN, ³Centers for Disease Control and Prevention, Atlanta, GA

Presenter: Amy Gaviglio, Connetics Consulting/CDC/APHL, amy.gaviglio@outlook.com

P–24
Guiding the Worldwide Newborn Screening Community: An Update on CLSI Products for Newborn Screening Programs
A. Gaviglio¹, L. Moon², R. Whitley²; ¹Connetics Consulting/CDC/APHL, Minneapolis, MN, ²CLSI, Malvern, PA

Presenter: Amy Gaviglio, Connetics Consulting/CDC/APHL, amy.gaviglio@outlook.com

P–25
PUCD Screening Pilot In Georgia
A. Wittenauer¹, W. Wilcox¹, P. Hall²; ¹Emory University, Atlanta, GA, ²Mayo Clinic, Rochester, MN

Presenter: Angela Wittenauer, Emory University, alwitte@emory.edu

P–26
Expecting Health’s Newborn Screening Genetic Counseling Internship: Creating Opportunities for Education and Collaboration around Newborn Screening for Genetic Counseling Students
M. Raia¹, N. Bonhomme¹, Brianne Miller²; ¹Expecting Health at Genetic Alliance, Damascus, MD ²Children’s National Hospital, Washington, DC

Presenter: Marianna Raia, Expecting Health, mraia@expectinghealth.org

P–27
Reaching the Unreached: A Flexible Education Model for Expecting Mothers
M. Raia¹, N. Bonhomme¹, B. Miller², J. Werker³; ¹Expecting Health at Genetic Alliance, Damascus, MD, ²Children’s National Hospital, Washington, DC, ³Indiana Community Health Clinic, Topeka, IN

Presenter: Marianna Raia, Expecting Health, mraia@expectinghealth.org
P–28*
Creating a Model for Collaborating around New Conditions in Newborn Screening: A Congenital Cytomegalovirus and Newborn Screening Work Group
B. Miller¹, N. Bonhomme²; ¹Children’s National Hospital, Washington, DC, ²Expecting Health at Genetic Alliance, Washington, DC
Presenter: Natasha Bonhomme, Expecting Health at Genetic Alliance, nbonhomme@expectinghealth.org

P–29
The Newborn Screening Information Center: A National Newborn Screening Education Website
K. Sprunck¹, B. Miller², A. Harris³, A. Keehn³, N. Bonhomme⁴; ¹National Institute for Children’s Health Quality, Boston, MA, ²Children’s National Hospital, Washington, DC, ³Health Resources and Services Administration, Washington, DC, ⁴Expecting Health at Genetic Alliance, Washington, DC
Presenter: Natasha Bonhomme, Expecting Health at Genetic Alliance, nbonhomme@expectinghealth.org

P–30*
What has been the Impact of a 17-year Comprehensive NBS Program in Mexico?
H. Cruz-Camino, C. Cantu-Reyna, C. Araiza-Lozano, Diana Laura Vazquez-Cantu and R. Gomez-Gutierrez, Genomi-k, Monterrey, NL, Mexico
Presenter: Hector Cruz-Camino, Genomi-k, hcruz@genomi-k.com

P–31
Analytical Performance Evaluation of the TaqMan SCID/SMA Plus Assay in Newborn Dried Blood Spots (DBS)
J. do Prado Silva¹, C. M. Crua da Silva², D. Alves Gomes Zauli¹, A.C. Perssonelli Sera²; ¹Instituto Hermes Pardini, Vespasiano, Minas Gerais, Brazil, ²Diagnósticos Laboratoriais Especializados
Presenter: Joice Silva, Grupo Pardini, joice.silva@grupopardini.com.br

P–32
Overnight Shipping Trial for Midwives and Smaller Facilities to Improve Transit Time from Collection to Receipt for the State of Kansas Newborn Screening Program
M.J. Mills¹, B. Adhikari²; ¹Kansas Department of Health and Environment, Topeka, KS, ²Centers for Disease Control and Prevention, Atlanta, GA
Presenter: Michelle Mills, Kansas Department of Health and Environment, michelle.j.mills@ks.gov
P–33
Review of Effectiveness of the Newborn Screening in Kentucky
H. Stone¹, L. Mott¹, S. Wei², A. Smith¹, D. O’Quinn¹, M. Yu¹; ¹Kentucky Division of Laboratory Services, Frankfort, KY, ²University of Kentucky, Lexington, KY
Presenter: Amy Smith and Daniel O’Quinn, Kentucky Division of Laboratory Services, lea.mott@ky.gov

P–34
Multiplexed LC-MS/MS Proteomic Pilot Study for Newborn Screening of Wilson Disease and Inborn Errors of Immunity in Washington State
C. Collins¹, A. Meuser¹, S. Sandin¹, C. Klippel¹, A. Singh², S. Shaunak², J. Hill², T. Shahbal², J. Uchytil², B. Officer², R. Dayuha³, P. Duong³, J. Thompson², S. Hahn³; ¹Key Proteo, Inc., Seattle, WA, Washington State Department of Health, Shoreline, WA, Seattle Children’s Research Institute, Seattle, WA
Presenter: Christopher Collins, Key Proteo, chris.collins@keyproteo.com

P–35
Monitoring Birthing Hospitals’ Best Practices through Performance Measurement Scorecard Implementation in Louisiana
N. Huynh¹, C. Harris¹, J. Herwehe², M. Brewer², T. Ibieta²; ¹Louisiana Genetic Disease Program, ²Louisiana Bureau of Family Health
Presenter: Ngoc Huynh, Louisiana Genetic Diseases Program, ngoc.huynh@la.gov

P–36 — Withdrawn

P–37
(Epi) Empire State of Mind: How Epidemiology Benefits Newborn Screening Data Sets
T. Kaye, H. Winslow, C. Wold, A. Dahle, S. Rosendahl and B-A. Bloom, Minnesota Department of Health
Presenter: Tory Kaye, Minnesota Department of Health, tory.kaye@state.mn.us

P–38
Open the Lines of Communication: Increasing Screening Partner Engagement through Improved Quality Reports
H. Winslow, T. Kaye and M. McCann, Minnesota Department of Health, St. Paul, MN
Presenter: Holly Winslow, Minnesota Department of Health, holly.winslow@state.mn.us
P–39
You Find What You Look For: Recognizing Patterns in Newborn Screening Data Sets to Engage Partners in QA/QI Initiatives
H. Winslow, T. Kaye, M. McCann, J. Simonetti and S. Rosendahl, Minnesota Department of Health, St. Paul, MN

**Presenter:** Holly Winslow, Minnesota Department of Health, holly.winslow@state.mn.us

P–40*
Developing and Updating the ACMG ACTion (ACT) Sheets and Algorithms
M. Lyon, M. Caisse and N. Rose, National Coordinating Center for the Regional Genetics Networks (NCC), Bethesda, MD

**Presenter:** Megan Lyon, National Coordinating Center for Regional Genetics Networks, mlyon@nccrcg.org

P–41 is now P–5a

P–42
Challenges and Conflicts of the Practical Application of Cystic Fibrosis Case Definitions for Newborn Screening Programs
J. Hale, A. Counihan and A. Comeau, New England Newborn Screening Program, Worcester, MA

**Presenter:** Jaime Hale, New England Newborn Screening Program, jaime.hale@umassmed.edu

P–43
Newborn Screening for the Homocystinurias (Classical and Remethylation Defects) using Methionine (Increased or Decreased) as a Marker: New England Experience

**Presenter:** Inderneel Sahai, New England Newborn Screening Program, inderneel.sahai@umassmed.edu

P–44*
Validation of a Two-tier Testing Algorithm for the Screening of X-linked Adrenoleukodystrophy — The New Jersey Experience
V.R. Floriani, M. O’Neill, P.R. Patel, M.M. Schachter and M.O. Carayannopoulos, New Jersey Newborn Screening Laboratory, Ewing, NJ

**Presenter:** Victoria Floriani, New Jersey Newborn Screening Laboratory, victoria.floriani@doh.nj.gov
P–45
Reclassification of Disease Risk using Psychosine and GALC Genotype in New York Infants Referred for Krabbe Disease
M. Nichols¹, C. Saavedra-Matiz¹, C. Stevens¹, J. Orsini², R. Wilson², C. Biski³, D. Wanger², M. Caggana¹; ¹Wadsworth Center, New York State Department of Health, Albany, NY, ²Thomas Jefferson University, Philadelphia, PA
Presenter: Joseph Orsini, Wadsworth Center, New York State Department of Health, joseph.orsini@health.ny.gov

P–46
The Game is Afoot: Using Newborn Screening Tools to Solve Two Cases of Mistaken Identity
Presenter: Virginia Sack, Wadsworth Center, New York State Department of Health, virginia.sack@health.ny.gov

P–47
Pre-analytical Problems Leading to Post-analytical Woes: Bad Data In, Bad Data Out
M. Caggana, C. Johnson and A. Showers, Wadsworth Center, New York State Department of Health, Albany, NY
Presenter: Christopher Johnson, Wadsworth Center, New York State Department of Health, christopher.johnson@health.ny.gov

P–48
Second-tier Testing for Congenital Adrenal Hyperplasia (CAH)
J. Dott, D. Kay, N.P. Tavakoli, M. Morrissey and M. Caggana, Wadsworth Center, New York State Department of Health, Albany, NY
Presenter: Norma Tavakoli, Wadsworth Center, New York State Department of Health, norma.tavakoli@health.ny.gov

P–49
Establishment of Gene Variant Phase from Dried Blood Spots Without Parent DNA: Feasibility and Validation
Presenter: Denise Kay, Wadsworth Center, New York State Department of Health, denise.kay@health.ny.gov
P–50
The Impact of a Guanidinoacetate Isobar on Newborn Screening Ontario’s Approach to Guanidinoacetate Methyltransferase Deficiency Screening
N. McIntosh, D. Durie, E. Desormeaux, A. Milks, P. Chakraborty, N. Lepage and M. Henderson, Newborn Screening Ontario, Ottawa, ON Canada
Presenter: Nathan McIntosh, Newborn Screening Ontario, nmcintosh@cheo.on.ca

P–51
An Evaluation of the Critical Congenital Heart Disease Screening Program — Newborn Screening Ontario
B. Milne, J. Milburn, R. Kirkwood, J. Marcardier and P. Chakraborty, Newborn Screening Ontario, Ottawa, ON Canada
Presenter: Bailey Milne, Newborn Screening Ontario, bmilne@cheo.on.ca

P–52
Implementation of Newborn Screening for X-Linked Adrenoleukodystrophy in North Carolina
K. Blake, J. Mills, S. Freeman, D. Pettit and S. Shone, North Carolina State Laboratory of Public Health, Raleigh, NC
Presenter: Kimberly Blake, North Carolina State Laboratory of Public Health, kimberly.blake@dhhs.nc.gov

P–53 — Withdrawn

P–54*
Improving Long-term Follow-up (LTFU) in a Newborn Screening (NBS) Program
A. Patterson1, J. Baysinger2; 1University of Oklahoma Health Science Center, Norman, OK, 2Oklahoma State Department of Health, Oklahoma City, OK
Presenters: Jennifer Baysinger, Oklahoma State Department of Health, jenniferxa@health.ok.gov and Amanda Patterson, University of Oklahoma Health Science Center, amanda.patterson@integrisok.com

P–55
Determination of Mucopolysaccharidosis Type II (MPS II) Enzymatic Activity in Dried Blood Spots using the PerkinElmer QSight® 225MD UHPLC Screening System
Presenter: Collin Hill, PerkinElmer, collin.hill@perkinelmer.com
P–56
Measurement of Lysophosphatidylcholine (26:0) in Dried Blood Spots via a Second-tier LC-MS/MS Assay using the PerkinElmer QSight® 225MD UHPLC Screening System
C. Hill, J. Trometer, R. Korathu and M. Giolito, PerkinElmer, Waltham, MA
Presenter: Collin Hill, PerkinElmer, collin.hill@perkinelmer.com

P–57
DryPCR in Detecting the Absence of SMN1, TREC and KREC from Extracted DNA from DBS
M. Siitonen, T. Helenius, H. Savela, M. Makinen, I. Alm-Ndiaye, V. Veikkolainen, M. Aaltoranta and M. Hjort, PerkinElmer Wallac, Turku, Finland
Presenter: Terhi Helenius, PerkinElmer Wallac, Terhi.Helenius@perkinelmer.com

P–58
Validation of an LC-MS Dried Blood Spot Enzyme Assay for the Screening of Mucopolysaccharidosis Type II
S. Blake¹, V. Robles¹, B. Migliore¹, J. Apoian¹, S. Young², E. Jalazo³, D. Bali², K. Clinard³, K. Blake⁴, D. Pettit⁴, J. Carter¹, H. Bilbrey¹, L. Torrice³, S. Shone⁴, C. Rehder², J. Muenzer³, L. Gehtland¹, M. Raspa¹, K. Kucera¹; ¹RTI International, Research Triangle Park, NC, ²Duke University, Durham, NC, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴North Carolina State Laboratory of Public Health, Raleigh, NC
Presenter: Samantha Blake, RTI International, slblake@rti.org

P–59
Does a Telephone Reminder After Receipt of a Mailed Recruitment Letter Impact Enrollment in a Newborn Screening Research Study?
Presenter: Lisa Gehtland, RTI International, lgehtland@rti.org

P–60
Early Check Newborn Screening for Angelman, Prader-Willi, and Dup15q Syndromes: Assay Preparation and Validation
B. Migliore¹, K. Kucera¹, A. Wheeler¹, E. Jalazo²; ¹RTI International, Research Triangle Park, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC
Presenter: Brooke Migliore, RTI International, bmigliore@rti.org
**P–61**

Using a Team Science Approach to Develop Short-term Follow-up Protocols and Educational Materials

M. Raspa¹, L. Percenti², M. Fort³, J. Watkins², K. Blake³, B. Wright¹, K. Kucera¹, M. Sontag⁴, S. Shone³, Y. Kellar-Guenter⁴; ¹RTI International, Research Triangle Park, NC, ²North Carolina Division of Child and Family Well-Being, Raleigh, NC, ³North Carolina State Laboratory of Public Health, Raleigh, NC, ⁴Center for Public Health Innovation, Littleton, CO

**Presenter:** Melissa Raspa, RTI International, mraspa@rti.org

**P–62**

Future Collaboration Between Early Intervention and Newborn Screening

S. Andrews¹, S. Blanchard², P. Chakraborty³, A. Isiaq¹, E. Jalazo⁴, S. Scott¹, D. Bailey¹; ¹RTI International, Research Triangle Park, NC, ²East Carolina University, Greenville, NC, ³Newborn Screening Ontario, Ottawa, ON Canada, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC

**Presenter:** Elizabeth Reynolds, RTI International, erreynolds@rti.org

**P–63**

Newborn Screening for Congenital Hypothyroidism & Screen Positive Exome Sequencing Among Neonates in a Tertiary Care Centre in Pondicherry, India — A Cross Sectional Study

V.B. Sugumaran¹, S. Sumathi², K. Karthikeyan²; ¹Saveetha Medical College & Hospital, SIMATS, Pondicherry, India, ²MGMCRIB, SBV, India

**Presenter:** Vinod Babu Sugumaran, Saveetha Medical College & Hospital, drvinodbabu@gmail.com

**P–64**

Comparative Analytical Performance of the Next-Generation Sebia CAPILLARYS 3 DBS Instrument for Newborn Hemoglobinopathy Disorder Screening

C. Williams¹, M.C. Dorley², T. Childs², K. Anderson¹, J. O’Leary¹; ¹Sebia, Atlanta, GA, ²Tennessee Department of Health: Division of Laboratory Services, Nashville, TN

**Presenter:** M. Christine Dorley, Tennessee Department of Health, m.christine.dorley@tn.gov

**P–65 — Withdrawn**
Implementation of Weekday Courier Service for Newborn Screening Specimens

H. Davis-Martin and B. Bair, South Carolina Dept of Health & Environmental Control, Columbia, SC

Presenter: S. Graham McCaskall, South Carolina Dept of Health & Environmental Control, mccasksg@dhec.sc.gov

Newborn Screening Dashboard: A Tool for Improving Tennessee Newborn Screening Quality

C. Lechner, M. Rumpler, M.C. Dorley, Y. Li, A. Ingram; 1Tennessee Department of Health: Division of Laboratory Services, Nashville, TN, 2Tennessee Department of Health: Division of Family Health and Wellness, Nashville, TN

Presenter: Charles Lechner, Tennessee Department of Health: Division of Laboratory Services, Charles.Lechner@tn.gov

Second-tier Confirmatory Testing for Hemoglobinopathies in Texas

S. Thompson, J. Lewis, R.C. Lee, S. Tanksley and J.M. Leavitt, Texas Department of State Health Services, Austin, TX

Presenter: John Leavitt, Texas Department of State Health Services, john.leavitt@dshs.texas.gov

Newborn Screening for Severe Combined Immunodeficiency in Texas Using Multiple of the Median

D. Seidel, K. Collins, R. Lee and S. Tanksley, Texas Department of State Health Services, Austin, TX

Presenter: Derek Seidel, Texas Department of State Health Services, derek.seidel@dshs.texas.gov

The Utility of a Five-Spot Punch in Hemoglobinopathy and SCID Testing to Investigate Inconsistent Results and the Educational Outreach

R. Tangalos, D. Seidel, C. Moore, E. Fitch and A. Schlabach, Texas Department of State Health Services, Austin, TX

Presenters: Amy Schlabach, Texas Department of State Health Services, amyschlabach@dshs.texas.gov and Rebecca Tangalos, Texas Department of State Health Services, rebecca.tangalos@dshs.texas.gov
P–71
Liquid Chromatography Tandem Mass Spectrometry for an Ever-Increasing Expansion of Newborn Screening Before or After DNA Sequencing

M. Gelb, M. Campagna and X. Hong, University of Washington, Seattle, WA

Presenter: Michael Gelb, University of Washington, gelb@uw.edu

P–72
Considering Screening Newborns for Congenital Cytomegalovirus in Washington State

C. Maloney¹,², C. Ng², M. Katsuyama², J. Thompson²; ¹University of Washington School of Public Health, Seattle, WA, ²Washington State Public Health Laboratories, Shoreline, WA

Presenter: Caitlin Maloney, University of Washington, cmm8019@uw.edu

P–73
KOH-based Buffer: A Cost-effective DNA Extraction Solution for Dried Blood Spots in SMA/SCID Assay

W. Dansithong, K. Logerquist, R. Hancey, A. Jeffrey, K. Ashment and A. Rohrwasser, Utah State Public Health Laboratory, Taylorsville, UT

Presenter: Warunee Dansithong, Utah State Public Health Laboratory, wdansithong@utah.gov

P–74
Improving Timeliness of Diagnosis for Single CFTR Mutation Results through Earlier Notification by NBS Follow-Up

M. Lowe and C. Crews, Virginia Department of Health, Richmond, VA

Presenter: Mary Lowe, Virginia Department of Health, mary.lowe@vdh.virginia.gov

P–75
Review and Expansion of Second Tier Screening for Cystic Fibrosis in Virginia

C. Alcorta¹, G. Cote¹, L.E. Lion¹, P. Hetterich¹, E. Hopkins¹, C. Crews², M. Lowe³; ¹Virginia Division of Consolidated Laboratory Services, Richmond, VA, ²Virginia Department of Health, Richmond, VA

Presenter: Christian Alcorta, Virginia Division of Consolidated Laboratory Services, christian.alcorta@dgs.virginia.gov
P–76
Successful Partnership Between NBS and IT Staff in Washington State
L. Christensen¹, R. Sampson¹, E. Rankin¹, J. Rhodes²; ¹Washington Public Health Laboratories, Shoreline, WA, ²Washington Health Technology Solutions, Olympia, WA
Presenter: Leann Christensen, Washington Public Health Laboratories, leann.christensen@doh.wa.gov

P–77 — Withdrawn

P–78
Reducing Screening False Positive Rate by Incorporating Additional Steroid Profile Analysis in Newborn Screening for Congenital Adrenal Hyperplasia
M. Berry, M. Loehe, M. Hansen, E. Bialk and M. Baker, Wisconsin State Laboratory of Hygiene, Madison, WI
Presenter: Michelle Berry, Wisconsin State Laboratory of Hygiene, michelle.berry@wisc.edu

P–79
Wyoming Newborn Screening Emergency Procedures Plan: Successes and Lessons Learned
C. Soule and E. Dubreus, Wyoming Department of Health, Cheyenne, WY
Presenter: Carleigh Soule, Wyoming Department of Health, carleigh.soule@wyo.gov

P–80
Rapid LC-MS/MS First-Tier Newborn Screening Assay with Equivalent Throughput to FIA-MS/MS
S. Isenberg, A. Pickens, C. Cuthbert and K. Petritis, Centers for Disease Control and Prevention, Atlanta, GA
Presenter: Samantha Isenberg, Centers for Disease Control and Prevention, sisenberg@cdc.gov

P–81*
Measurement of Non-reducing Terminal Glycosaminoglycan Fragment Increases Specificity of Second-Tier Testing for Mucopolysaccharidosis Type I (MPS I)
S. Smith¹, M. Gelb², Z. Herbst², J. Dellagatta¹, S. Chernenkoff¹, T. Donti¹, H. Khaledi³; ¹PerkinElmer Genomics, Pittsburgh, PA, ²University of Washington, Seattle, WA, ³GelbChem, LLC, Seattle, WA
Presenter: Sara Smith, PerkinElmer Genomics, sara.smith@perkinelmer.com
## Symposia History


### Newborn Screening Symposium (2020–present)

<table>
<thead>
<tr>
<th>Year</th>
<th>Location</th>
<th>Year</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1981</td>
<td>Austin, TX</td>
<td>2002</td>
<td>Phoenix, AZ</td>
</tr>
<tr>
<td>1982</td>
<td>Chicago, IL</td>
<td>2004</td>
<td>Atlanta, GA</td>
</tr>
<tr>
<td>1984</td>
<td>Orlando, FL</td>
<td>2005</td>
<td>Portland, OR</td>
</tr>
<tr>
<td>1985</td>
<td>Columbus, OH</td>
<td>2007</td>
<td>Minneapolis, MN</td>
</tr>
<tr>
<td>1986</td>
<td>Austin, TX</td>
<td>2008</td>
<td>San Antonio, TX</td>
</tr>
<tr>
<td>1988</td>
<td>Portland, OR</td>
<td>2010</td>
<td>Orlando, FL</td>
</tr>
<tr>
<td>1989</td>
<td>New Orleans, LA</td>
<td>2011</td>
<td>San Diego, CA</td>
</tr>
<tr>
<td>1991</td>
<td>Saratoga, NY</td>
<td>2013</td>
<td>Atlanta, GA (with ISNS)</td>
</tr>
<tr>
<td>1992</td>
<td>Raleigh, NC</td>
<td>2014</td>
<td>Anaheim, CA</td>
</tr>
<tr>
<td>1994</td>
<td>Seattle, WA</td>
<td>2016</td>
<td>St. Louis, MO</td>
</tr>
<tr>
<td>1995</td>
<td>Corpus Christi, TX</td>
<td>2017</td>
<td>New Orleans, LA</td>
</tr>
<tr>
<td>1996</td>
<td>Boston, MA</td>
<td>2019</td>
<td>Chicago, IL</td>
</tr>
<tr>
<td>1998</td>
<td>San Diego, CA</td>
<td>2020</td>
<td>Virtual</td>
</tr>
<tr>
<td>1999</td>
<td>St. Louis, MO</td>
<td>2021</td>
<td>Virtual</td>
</tr>
<tr>
<td>2001</td>
<td>Raleigh, NC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Future APHL Meetings

APHL ID Lab Con 2023
Atlanta, GA • March 13–15, 2023

APHL 2023
Sacramento, CA • May 22–25, 2023

13th National Conference on Laboratory Aspects of Tuberculosis
Atlanta, GA • June 12–13, 2023

Joint APHL 2023 Newborn Screening Symposium and the International Society for Neonatal Screening Meeting
Sacramento, CA • October 15–19, 2023

Association of Public Health Laboratories
8515 Georgia Ave, Suite 700
Silver Spring, MD 20910
240.485.2745 • www.aphl.org